Table 4.
Oncological results and adjuvant treatments
| Variables | Open (N = 93/91)* | VATS (N = 62) | Combined (N = 155/153)* | p-value |
|---|---|---|---|---|
| Histology | 0.6 | |||
| Adenocarcinoma | 69% (64) | 72% (45) | 71% (109) | |
| Squamous cell carcinoma | 23% (21) | 20% (12) | 21% (33) | |
| Other | 9% (8) | 8% (5) | 8% (13) | |
| pTNM-stage | 0.3 | |||
| CR(T0N0) | 1% (1) | 1.6% (1) | 1.3% (2) | |
| Ia | 11% (10) | 10% (6) | 9% (14) | |
| Ib | 11% (10) | 18% (11) | 8% (12) | |
| IIa | 11% (10) | 16% (10) | 13% (20) | |
| IIb | 15% (14) | 18% (11) | 17% (26) | |
| IIIa | 32% (30) | 31% (19) | 30% (46) | |
| IIIb | 15% (14) | 23% (14) | 19% (30) | |
| IIIc | 2% (2) | – | ||
| IV | 1% (1) | 3% (2) | 2% (3) | |
| pN-disease | 0.6 | |||
| pN0 | 45% (42) | 44% (27) | 45% (69) | |
| pN1 | 16% (15) | 18% (11) | 17% (26) | |
| pN2 | 37% (34) | 39% (24) | 37% (58) | |
| pN3 | 2% (2) | – | 1% (2) | |
| Overall downstaging | 40% (37) | 45% (28) | 42% (65) | 0.6 |
| Adjuvant chemotherapy | 21% (19) | 34% (21) | 26% (40) | 0.07 |
| Time from surgery to adjuvant therapy(days) | 48 (IQR 32–61) | 32 (IQR 30–40) | 39 (IQR 30–44) | 0.09 |
| Cycles numbers | 3 (IQR 2–4) | 4 (IQR 3–5) | 4 (IQR 2–4) | 0.08 |
| Suspension for toxicity | 26% (5) | 19% (4) | 22% (9) | 0.059 |
| Adjuvant radiotherapy | 56% (51) | 31% (19) | 46% (70) | 0.002 |
| Immunotherapy | 1% (1) | 1.6% (1) | 1% (2) | 0.08 |
| Target therapy | 9% (8) | 8% (5) | 9% (13) | 0.5 |
| Recurrence | 0.1 | |||
| Loco-regional | 11% (10) | 13% (8) | 4% (26) | |
| Systemic | 49% (45) | 42% (26) | 46% (71) | |
| Median recurrence time (months) | 16.8 (IQR 8.4–40) | 18 (IQR 12–28) | 18(IQR 8–34) | 0.9 |
IQR interquartile range, CR complete response